Testing the evolution process of prostate‐specific antigen in early stage prostate cancer: what is the proper underlying model?

This paper empirically tests a model of stochastic evolutions of prostate-specific antigen (PSA), a trigger for intervention in an early stage prostate cancer surveillance program. It conducts hypothesis testing of the Geometric Browning Motion model based on its attributes of independent increments and linearity of the variance in the increment length versus a wide range of stochastic and deterministic alternatives. These alternatives include the currently accepted deterministic growth model. The paper reports strong empirical evidence in favour of the Geometric Browning Motion model. A model that best describes PSA evolution is a prerequisite to the establishment of decision-making criteria for abandoning active surveillance (i.e. a strategy that involves close monitoring) in early stage prostate cancer. Thus, establishing empirically the type of PSA process is a first step toward the identification of more accurate triggers for abandoning active surveillance and starting treatment while the chances of curing the disease are still high.

[1]  Ram Rup Sarkar,et al.  Cancer self remission and tumor stability-- a stochastic approach. , 2005, Mathematical biosciences.

[2]  Alexandre Mamedov,et al.  Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  C Metcalfe,et al.  Current strategies for monitoring men with localised prostate cancer lack a strong evidence base: observational longitudinal study , 2009, British Journal of Cancer.

[4]  A. Mood The Distribution Theory of Runs , 1940 .

[5]  Amiram Gafni,et al.  A stochastic approach to risk management for prostate cancer patients on active surveillance. , 2011, Journal of theoretical biology.

[6]  Peter C Albertsen,et al.  Prostate cancer diagnosis and treatment after the introduction of prostate-specific antigen screening: 1986-2005. , 2009, Journal of the National Cancer Institute.

[7]  Anna Kettermann,et al.  Prostate-specific antigen kinetics during follow-up are an unreliable trigger for intervention in a prostate cancer surveillance program. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  C. Eisenhart,et al.  Tables for Testing Randomness of Grouping in a Sequence of Alternatives , 1943 .

[9]  Thomas L. Jackson,et al.  A mathematical model of prostate tumor growth and androgen-independent relapse , 2003 .

[10]  J. Davidson Stochastic Limit Theory , 1994 .

[11]  D. Veestraeten An alternative approach to modelling relapse in cancer with an application to adenocarcinoma of the prostate. , 2006, Mathematical biosciences.

[12]  A. Lo,et al.  The Size and Power of the Variance Ratio Test in Finite Samples: a Monte Carlo Investigation , 1988 .

[13]  Liying Zhang,et al.  Modeling prostate specific antigen kinetics in patients on active surveillance. , 2006, The Journal of urology.

[14]  P W A Dayananda,et al.  Prostate cancer: progression of prostate-specific antigen after external beam irradiation. , 2003, Mathematical biosciences.

[15]  Kazuyuki Aihara,et al.  Development of a mathematical model that predicts the outcome of hormone therapy for prostate cancer. , 2010, Journal of theoretical biology.

[16]  Mikhail M. Shvartsman,et al.  A stochastic model for PSA levels: behavior of solutions and population statistics , 2006, Journal of mathematical biology.

[17]  Donald E Bailey,et al.  Active surveillance for early‐stage prostate cancer , 2008, Cancer.

[18]  J. T. Kemper,et al.  A stochastic model for prostate-specific antigen levels. , 2004, Mathematical biosciences.

[19]  A W Partin,et al.  Natural history of progression after PSA elevation following radical prostatectomy. , 1999, JAMA.

[20]  Pankaj K Choudhary,et al.  Critical analysis of prostate‐specific antigen doubling time calculation methodology , 2006, Cancer.